Radius Health Inc. announced the appointment of Michael S. Wyzga as President and Chief Executive Officer and a member of the Board of Directors, effective with the retirement of C. Richard Lyttle, PhD from the company to advance a Phase 3 osteoporosis drug.
Wyzga joins Radius after serving as Executive Vice President, Finance and Chief Financial Officer of Genzyme. Lyttle will remain with the company during the management transition as interim Chief Scientific Officer following his retirement as President and CEO.
In addition, Radius announced that Louis Brenner, MD, has been appointed Chief Medical Officer and that board member Kurt Graves has been elected Chairman of the board.
“With our lead osteoporosis program BA058 well into Phase 3, the breakthrough BA058 Microneedle Patch proving itself in the clinic, significant financing in place, and a clear strategy to take Radius to the commercial stage, the timing is right to add new strength to the Board and executive management and for me to transition from Radius,” says Lyttle.
Release Date: Dec. 5, 2011
Source: Radius Health Inc.